Abstract
Background: The use of nanobiomaterials is increasing each day. Among the immense variety of nanomaterials developed and studied the hydroxyapatite is one of the most ones.
Objective: In this study we developed and tested nano-hydroxyapatite dopped with Ho-166 for bone cancer. Results: The results showed that the nano-hydroxyapatite dopped with Ho-166 has a great affinity for the bone. Conclusion: The pre-clinical studies support the use as a nano-radiopharmaceuticals for bone cancer treatment and diagnosis.Keywords: Radiopharmaceuticals, nanotechnology, oncology, scanning electron microscopy, transmission electron microscopy.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Nano-Hydroxyapatite Doped with Ho-166 as Drug Delivery System for Bone Cancer Therapy and Diagnosis: Developing a Theragnostic Radiopharmaceuticals
Volume: 17 Issue: 3
Author(s): Franciana Maria Rosa da Silva, Julio Cezar de Almeida, Elizabeth Eugenio de Mello Oliveira, Marta de Souza Albernaz, Alexandre Malta Rossi and Ralph Santos-Oliveira
Affiliation:
Keywords: Radiopharmaceuticals, nanotechnology, oncology, scanning electron microscopy, transmission electron microscopy.
Abstract: Background: The use of nanobiomaterials is increasing each day. Among the immense variety of nanomaterials developed and studied the hydroxyapatite is one of the most ones.
Objective: In this study we developed and tested nano-hydroxyapatite dopped with Ho-166 for bone cancer. Results: The results showed that the nano-hydroxyapatite dopped with Ho-166 has a great affinity for the bone. Conclusion: The pre-clinical studies support the use as a nano-radiopharmaceuticals for bone cancer treatment and diagnosis.Export Options
About this article
Cite this article as:
Silva Maria Rosa da Franciana, Almeida Cezar de Julio, Oliveira Eugenio de Mello Elizabeth, Albernaz de Souza Marta, Rossi Malta Alexandre and Santos-Oliveira Ralph, Nano-Hydroxyapatite Doped with Ho-166 as Drug Delivery System for Bone Cancer Therapy and Diagnosis: Developing a Theragnostic Radiopharmaceuticals, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1871520616666151110130428
DOI https://dx.doi.org/10.2174/1871520616666151110130428 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Cardiovascular Calcification in Uremia
Current Vascular Pharmacology Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine
Current Radiopharmaceuticals Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Current Cancer Therapy Reviews The Regulation of FoxP3-Expressing Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Marine Peptides for Preventing Metabolic Syndrome
Current Protein & Peptide Science A Possible Role for Interleukin 37 in the Pathogenesis of Behcet's Disease
Current Molecular Medicine Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Protective Effect of Anthocyanins on Radiation-induced Hippocampal Injury through Activation of SIRT3
Current Pharmaceutical Design Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design The Use of Cyclodextrins Nanoparticles for Oral Delivery
Current Medicinal Chemistry NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting <i>HIF1A</i> in <i>NONO-TFE3</i> Translocation Renal Cell Carcinoma
Current Cancer Drug Targets Current Status of Newer Antiinfectives
Recent Patents on Anti-Infective Drug Discovery Beneficial or Detrimental Effects of Carotenoids Contained in Food: Cell Culture Models
Mini-Reviews in Medicinal Chemistry Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued)